Novartis targets Alexion's fiefdom after showing PNH patients can safely switch from Soliris Ionis strikes deal to buy back lipid disease spinout Akcea The top 10 global R&D institutes ILC: Clinical failure or course correction? Gilead’s NASH programs could be both ESC: Novartis' twice-yearly inclisiran cuts bad cholesterol by at least 30% in nearly all patients Unum's CAR-T tech—and research team—lands at Czech biotech Sotio for $8.1M ESC: MyoKardia's mavacamten boosts heart function in phase 3, teeing up 2021 filing ILC: GSK's antisense hep B hopeful hits positives in midstage test, rivaling RNA therapies Musk's Neuralink demos revamped brain-reading chip in live pigs Cats point the way to potential COVID-19 remedies Featured Story | By Nick Paul Taylor Novartis has presented midphase data showing paroxysmal nocturnal hemoglobinuria patients can safely transition from Alexion’s Soliris to its experimental oral candidate LNP023. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Ionis Pharmaceuticals has struck a deal to buy its lipid disorder spinout Akcea Therapeutics. The deal will see Ionis pay around $500 million to acquire the 24% of Akcea that it doesn’t already own. read more By Ben Adams Many new drugs and diagnostics would never have seen the light of day if it wasn’t for academic and R&D institutes. Our top 10 are the most prolific when it comes to collabs and research pacts with the life sciences industry, with many big-name scientists and alumni working at biotech spin-outs from our leading institutes. read more By Amirah Al Idrus 2019 was not a good year for Gilead’s fatty liver programs. Its lead prospect did worse than placebo in not one, but two, phase 3 studies, while its combination treatments also fell short in phase 2. It’s not letting those efforts go to waste, though—in studies presented at this year’s virtual International Liver Congress, Gilead and partner PathAI suggest improvements to NASH drug development. read more By Conor Hale Despite pandemic-related setbacks in its clinical program earlier this year, Novartis has continued to stack up favorable data for its cholesterol drug inclisiran—with a new analysis showing 99% of treated patients cut their LDL levels by 30% or more. read more By Amirah Al Idrus It’s no secret that Unum Therapeutics has had a tough run—in March, the company cut more than half its staff and wound down its clinical work in a bid to shore up a preclinical CAR-T prospect. Now, that program, along with the technology behind it, has found a new home: Sotio, a Prague-based biotech developing multiple types of cancer treatments. read more By Conor Hale A phase 3 pivotal trial of MyoKardia's mavacamten has demonstrated that the first-in-class drug can perform as a disease-specific therapy for hypertrophic cardiomyopathy, or HCM, by preventing the thickened heart muscle associated with the disease from obstructing the flow of blood. read more By Ben Adams While the likes of Vir and J&J were highlighting their RNAi approaches to treating hepatitis B at the International Liver Congress this week, GlaxoSmithKline and Ionis quietly dropped their data using a rival MOA. read more By Conor Hale Elon Musk’s brain-burrowing Neuralink venture has debuted the latest version of its mind-reading chip, showing it can work in live animals. read more By Arlene Weintraub University of Alberta scientists reported that a drug being developed by Anivive Lifesciences to treat feline infectious peritonitis prevented human coronaviruses from replicating in cell studies. They believe the drug should be rushed into human trials to treat patients with COVID-19, given that it has proven safe and effective in cats. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Evotec Two informative webcasts will present practical and methodological approaches to preclinical drug abuse liability assessment Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Oracle Health Sciences Patient-facing digital technologies are playing an important role in clinical trials for new drugs and medical devices, to the point where conducting virtual trials is becoming mainstream. But terms like remote trials, direct-to-patient trials, hybrid trials, decentralized trials, and more all add to the confusion of what makes a trial "virtual." Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Thermo Fisher Scientific How to select the right dosage form for your Phase I clinical supply. Sponsored by: Thermo Fisher Scientific Quality by Design (QbD) reduces risk within drug development, while bringing therapies to market quicker. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 